Silon Tx aims to develop and test smart, versatile and adaptable therapeutic Hsp27-AS0 Apatorsen nanoparticles capable of precisely targeting Hsp27 mRNA to restore treatment-sensitivity and improve length and quality of life. The first application, dedicated to the treatment of advanced forms of prostate cancer, promises to offer new hope to patients.
OUR HISTORY
Founded in 2024,
SILON Therapeutics is the result of more than twenty years of cutting-edge research in oncology at the interface of biology and chemistry, by Dr. Palma Rocchi's lab.
This innovative work, focused on prostate cancer, has led to major advances in understanding the mechanisms of treatment resistance and the development of new therapeutic strategies, such as the development of OGX-427 (Apatorsen), an antisense oligonucleotide (ASO) specifically targeting stress induced Hsp27 mRNA, and aimed at blocking the occurrence of treatment resistance.
Apatorsen has been patented with licensed and clinical trial phase I/II was performed in patients with PC but also, lung bladder and ovarian cancers.
PROSTATE CANCER
A MAJOR PUBLIC HEALTH ISSUEProstate cancer (PC) is the most commonly diagnosed male malignant tumor worldwide and the third leading cause of cancer death in men. A man is diagnosed with PC every 2 minutes and a man dies from it every 15 minutes.
GLOBOCAN Estimates ofIncidence and Mortality Worldwide for 36 Cancers in 185
Countries. CA CANCER J CLIN 2021;71:209–249
Almost one in two men are diagnosed late, at advanced stages with poor prognosis. Although first- and second-generation hormone therapies and taxane-based chemotherapies are the usual treatments for advanced PC, they do not block the progression to treatment resistance.
cases
New therapeutic approaches have recently been tested, such as targeted radionuclide therapy.
However, the anti-tumor effects are still limited, with an impact on overall survival of 4 months.
Tailored made effective and well tolerated treatments for treatment resistant PC are a priority
OUR TECHNOLOGY
We recently developed and world-wide patented novel generation lipid-modified antisense oligonucleotides (LASOs) that impressively enhance stability, bioavailability, and cellular delivery of mRNA-targeting therapies with improved therapeutic efficacy.
This technology can also be adapted to synthesize other nucleolipid conjugates and thus design versatile and modular nanoobjects for precision medicine.
OUR GOAL
Our aim is to demonstrate the therapeutic benefit potential of these smart nanoobjects by developing a totally disruptive drug candidate for advanced prostate cancer. Our cutting-edge approach will indeed provide a dual benefit: more effective treatment with reduced toxicity.
With its precision and rapid production capabilities, this technology has the potential to revolutionize the treatment of advanced prostate cancer by delivering personalized, targeted care.
Treats AND blocks resistance to treatments
High specificity Customized treatment
Limited toxicity Specific to tumor cells
Fast manufacturing Similar to RNA vaccines
A TRUE “GAME CHANGER”
Conventional treatment
A single molecule
Resistance to treatments
High toxicity
Damages to healthy cells
Random treatment
Many adverse effects
Low manufacturing
10 years
Our drug candidate
Cocktail of active compounds
Treatment resistance blockage
Limited toxicity
No effect on healthy cells
Personalized treatment
No adverse effects
Fast manufacturing
Few months
THE PROSTATE CANCER THERAPY MARKET
In the US, the cost of a standard treatment for late-diagnosed prostate cancer ranges between $70 000 and $700,000 per patient.
Our drug will be positioned as 3rd line therapy and should therefore concern between 300,000 and 500,000 new patients each year.
Global Hormone Refractory Prostate Cancer Market
Compound annual growth rate (CAGR) of 9.8% during the forecast period from 2024 to 2033
OUR TEAM
Laurence COLLEAUX
Senior Research director at CNRS
CEO and co-founder
Unité Inserm ERL 1326 RNAnoTher
Genetic disease specialist
Palma ROCCHI
INSERM Research Director
CSO and Co-founder
Director of Inserm ERL
U1326 “RNAnoTher”
Worldwide expert in mRNA targeting , Nanomedicine and Theranostic for personalized therapy
Michel CAMPLO
MCF-HDR-CEx
Associate Professor
COO and co-founder
Unité Inserm ERL 1326
RNAnoTher
Organic chemist specialized in the
design of bioactive molecules.
David TAIEB
MD-PhD-HDR, PU-PH
Head of the department of Nuclear
Medicine at APHM/AMU
CMO and co-founder
Team member of ERL INSERM
U1326 RNAnoTher
Expert in targeted radionuclide therapy
Jean-Manuel RAIMUNDO
Full Professor
CTO and co-founder
CNRS CINaM UMR7325
Specialist in molecular and
supramolecular engineering of
organic molecules for biomedical
applications.
OUR BOARD
Frederic BENETON
Polytechnique (X94)
Master 2 Physiologie (2015)
Serial entrepreneur in healthtech
Christine GUILLEN
Pharm-D ,
Start-up co-founder,
C_level manager in innovation-based
healthcare start-up